Skip to main content
Erschienen in: BMC Urology 1/2020

Open Access 01.12.2020 | Research article

Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma

verfasst von: Shota Omura, Satoru Taguchi, Shogo Miyagawa, Ryuki Matsumoto, Mio Samejima, Naoki Ninomiya, Kazuki Masuda, Yu Nakamura, Tsuyoshi Yamaguchi, Manami Kinjo, Mitsuhiro Tambo, Takatsugu Okegawa, Eiji Higashihara, Hiroshi Fukuhara

Erschienen in: BMC Urology | Ausgabe 1/2020

Abstract

Background

Although the albumin-to-globulin ratio (AGR) is a promising biomarker for various malignancies, few studies have investigated its prognostic significance for upper tract urothelial carcinoma (UTUC).

Methods

This retrospective study conformed to the REporting recommendations for tumour MARKer prognostic studies (REMARK) guideline. We reviewed 179 patients with UTUC who underwent radical nephroureterectomy at our institution between 2008 and 2018. Associations of preoperative clinicopathological factors, including the AGR, with cancer-specific survival (CSS) and overall survival (OS) were assessed. The Cox proportional hazards model was used for univariate and multivariable analyses. AGR was dichotomized as < 1.25 and ≥ 1.25, according to the most discriminatory cutoff determined from the receiver operating characteristic curve analysis.

Results

During a median follow-up of 34 months after surgery, 37 patients died from UTUC and 13 died of other causes. The preoperative AGR significantly correlated with pathological T stage, pathological N stage, and adjuvant chemotherapy. Multivariate analyses demonstrated that a decreased (< 1.25) preoperative AGR was an independent poor prognostic factor for both CSS (hazard ratio [HR] = 2.81, P <  0.01) and OS (HR = 2.09, P <  0.05).

Conclusions

Preoperative AGR < 1.25 might serve as a useful prognostic marker for patients with UTUC undergoing radical nephroureterectomy.
Hinweise

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12894-020-00700-8.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AGR
Albumin-to-globulin ratio
AUC
Area under the curve
CSS
Cancer-specific survival
IQR
Interquartile range
OS
Overall survival
ROC
Receiver operating characteristic
UTUC
Upper tract urothelial carcinoma

Background

Upper tract urothelial carcinoma (UTUC) is a relatively rare malignancy that accounts for 5–10% of urothelial carcinomas and generally has a poor prognosis [1, 2]. Radical nephroureterectomy with bladder cuff excision is the gold standard treatment for nonmetastatic UTUC [3], whereas up to 19% of patients with UTUC have metastasis upon initial presentation [4].
Clinicopathological factors [515] including laboratory markers [1115] serve as prognostic markers for UTUC. In contrast, the significance of the albumin-to-globulin ratio (AGR), which serves as a useful biomarker for various malignancies [1626], has not been fully investigated in UTUC [2326]. Therefore, the present study assessed the significance of the association of preoperative AGR on oncological outcomes of patients with UTUC undergoing radical nephroureterectomy.

Methods

This retrospective study conformed to the REporting recommendations for tumour MARKer prognostic studies (REMARK) guideline [27] (Supplementary Table 1 shows the REMARK checklist of the present study). This study was approved by the internal institutional review board of Kyorin University School of Medicine (approval number: 1154).

Patients

We retrospectively reviewed 185 consecutive patients who underwent radical nephroureterectomy with curative intent at Kyorin University Hospital between 2008 and 2018. We excluded six patients because of pathological diagnoses of urothelial dysplasia (n = 3), renal cell carcinoma (n = 2), and squamous cell carcinoma (n = 1), which left 179 available for analysis.

Preoperative AGR

Routine preoperative blood tests including serum total protein and albumin levels (g/dl) were performed within 1 month before surgery. The AGR was calculated using the following formula: AGR = [albumin / (total protein – albumin)]. No patient had active infectious disorders during the blood tests.

Endpoints and follow-up

We assessed the associations of preoperative clinicopathological factors, including the AGR, with cancer-specific survival (CSS) and overall survival (OS). The follow-up period started on the day of surgery. Follow-up information was obtained as of October 2018.

Statistical analysis

Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value of the AGR. Sensitivity, specificity and area under the curve (AUC) were calculated using a 2 × 2 contingency table for different cutoff values of the AGR. The optimal cutoff value of the AGR was determined by maximization of the Youden’s index [Sensitivity − (1 − Specificity)]. Relations of the AGR to other variables were evaluated using the χ2 test or Spearman’s rank correlation coefficient. Survival curves were generated using the Kaplan–Meier method and compared using log-rank tests. The Cox proportional hazard regression model was used for univariate and multivariate analyses. All statistical analyses were performed using JMP Pro version 14.0.0 (SAS Institute, Cary, NC, USA). P <  0.05 was considered to indicate a significant difference.

Results

Patients’ baseline characteristics are summarized in Table 1. The median follow-up was 34 months (interquartile range [IQR], 17–63) months. Thirty-seven patients died from UTUC and 13 died of other causes. ROC curve analysis identified 1.25 as the most discriminatory cutoff value of AGR by maximization of the Youden’s index [Sensitivity − (1 − Specificity)] for both endpoints of CSS and OS (Fig. 1).
Table 1
Patient characteristics (n = 179)
Parameter
Value
Age at surgery, years, median (IQR)
75 (66–79)
Sex, no. (%):
 Male
132 (73.7)
 Female
47 (26.3)
Surgical technique, no. (%):
 Open
16 (8.9)
 Laparoscopic
163 (91.1)
Tumor location, no. (%):
 Renal pelvis
96 (53.6)
 Ureter
81 (45.3)
 Both
2 (1.1)
Tumor grade, no. (%):
 G1
10 (5.6)
 G2
94 (52.5)
 G3
75 (41.9)
Pathological T stage, no. (%):
 Ta/1/is
91 (50.8)
 T2
13 (7.3)
 T3
70 (39.1)
 T4
5 (2.8)
Pathological N stage, no. (%):
 N0/x
157 (87.7)
 N1
16 (8.9)
 N2
6 (3.4)
 N3
0 (0)
Adjuvant chemotherapy, no. (%):
 Yes
39 (21.8)
 No
140 (78.2)
Bladder cancer status, no. (%):
 No
145 (81.0)
 Previous
19 (10.6)
 Synchronous
15 (8.4)
AGR, median (IQR)
1.41 (1.18–1.63)
Follow-up duration, months, median (IQR)
35 (17–63)
Abbreviations: AGR albumin-to-globulin ratio, IQR interquartile range
χ2 test revealed pathological T stage (≥T3, P <  0.01), pathological N stage (N1–3, P <  0.01), and adjuvant chemotherapy (yes, P <  0.05) to be significantly associated with AGR < 1.25, while the other variables (sex, surgical technique, tumor location, tumor grade and previous or synchronous bladder cancer) were not. Spearman’s rank correlation coefficient showed a weakly significant negative correlation between age at surgery and the AGR (ρ = − 0.25, P <  0.01).
Kaplan–Meier curves with log-rank tests showed significant associations of preoperative AGR < 1.25 with shorter CSS (Fig. 2) and OS (Fig. 3). Multivariate Cox proportional hazard regression analyses identified preoperative AGR < 1.25 as an independent poor prognostic factor for both CSS (hazard ratio [HR] = 2.81, P <  0.01) (Table 2) and OS (HR = 2.09, P <  0.05; Table 3).
Table 2
Univariate and multivariate Cox proportional hazard regression analyses of CSS
Parameter
Cutoff
Univariate
Multivariate
HR (95% CI)
P
HR (95% CI)
P
Age at surgery
Continuous
1.03 (0.99 to 1.07) per score
0.07
1.03 (0.99 to 1.08) per score
0.18
Sex
Male
Reference
<  0.05*
Reference
0.14
 
Female
2.15 (1.09 to 4.13)
 
1.73 (0.83 to 3.51)
 
Surgical technique
Open
Reference
0.16
Reference
0.21
 
Laparoscopic
0.50 (0.23 to 1.34)
 
2.26 (0.63 to 8.93)
 
Tumor location
Renal pelvis or both
Reference
0.56
Reference
0.72
 
Ureter
1.21 (0.63 to 2.33)
 
1.14 (0.55 to 2.42)
 
Tumor grade
G1/2
Reference
<  0.01*
Reference
<  0.05*
 
G3
4.10 (2.07 to 8.66)
 
2.56 (1.07 to 6.50)
 
Pathological T stage
≤T2
Reference
<  0.01*
Reference
0.06
 
≥T3
3.67 (1.88 to 7.59)
 
2.51 (0.96 to 6.70)
 
Pathological N stage
N0/x
Reference
<  0.01*
Reference
0.20
 
N1–3
4.82 (2.20 to 9.77)
 
2.21 (0.65 to 7.00)
 
Adjuvant chemotherapy
Yes
Reference
<  0.05*
Reference
0.51
 
No
0.49 (0.25 to 0.97)
 
1.36 (0.55 to 3.37)
 
Previous or synchronous bladder cancer
No
Reference
<  0.01*
Reference
<  0.01*
 
Yes
3.61 (1.83 to 6.92)
 
3.49 (1.66 to 7.19)
 
AGR
≥1.25
Reference
<  0.01*
Reference
<  0.01*
 
< 1.25
3.90 (2.02 to 7.79)
 
2.81 (1.34 to 6.10)
 
Abbreviations: HR hazard ratio, CI confidence interval, AGR albumin-to-globulin ratio
*Statistically significant
Table 3
Univariate and multivariate Cox proportional hazard regression analyses of OS
Parameter
Cutoff
Univariate
Multivariate
HR (95% CI)
P
HR (95% CI)
P
Age at surgery
Continuous
1.03 (1.00 to 1.07) per score
<  0.05*
1.03 (0.99 to 1.07) per score
0.07
Sex
Male
Reference
0.08
Reference
0.23
 
Female
1.72 (0.93 to 3.07)
 
1.48 (0.77 to 2.76)
 
Surgical technique
Open
Reference
<  0.05*
Reference
0.60
 
Laparoscopic
0.44 (0.23 to 0.98)
 
1.33 (0.47 to 4.03)
 
Tumor location
Renal pelvis or both
Reference
0.92
Reference
0.88
 
Ureter
1.03 (0.58 to 1.80)
 
1.05 (0.57 to 1.94)
 
Tumor grade
G1/2
Reference
<  0.01*
Reference
<  0.05*
 
G3
2.61 (1.49 to 4.67)
 
2.15 (1.03 to 4.52)
 
Pathological T stage
≤T2
Reference
<  0.01*
Reference
0.27
 
≥T3
2.30 (1.32 to 4.08)
 
1.54 (0.71 to 3.35)
 
Pathological N stage
N0/x
Reference
<  0.01*
Reference
0.09
 
N1–3
4.32 (2.14 to 8.12)
 
2.56 (0.87 to 7.09)
 
Adjuvant chemotherapy
Yes
Reference
0.33
Reference
0.23
 
No
1.36 (0.73 to 2.43)
 
1.62 (0.74 to 3.61)
 
Previous or synchronous bladder cancer
No
Reference
<  0.01*
Reference
<  0.05*
 
Yes
2.43 (1.28 to 4.39)
 
1.99 (1.01 to 3.75)
 
AGR
≥1.25
Reference
<  0.01*
Reference
<  0.05*
 
< 1.25
2.90 (1.66 to 5.15)
 
2.09 (1.12 to 3.92)
 
Abbreviations: HR hazard ratio, CI confidence interval, AGR albumin-to-globulin ratio
*Statistically significant

Discussion

The present study demonstrates that a decreased (< 1.25) preoperative AGR was an independent indicator of poor prognosis for CSS and OS of patients with UTUC treated with radical nephroureterectomy.
Clinicopathological factors that serve as prognostic factors for UTUC [515] include sex [5], age [6], tumor size [7, 8], ureteral involvement [9], and body mass index [10], as well as laboratory markers [1115] such as the neutrophil-to-lymphocyte ratio [11, 12], albumin [13], hemoglobin [14], and the prognostic nutritional index [15]. On the other hand, the AGR has been reported as a useful biomarker in various malignancies [1626], including urological cancers [2026]. However, the significance of the AGR as a prognostic marker for UTUC has not been fully investigated [2326]. For example, a study of a Chinese cohort of 187 operable patients with UTUC [23] demonstrated that AGR < 1.45 is an independent risk factor for poorer CSS and OS. Another study of a Chinese cohort of 620 patients with UTUC treated with radical nephroureterectomy found that AGR < 1.45 is an independent predictor of adverse pathologic features, recurrence-free survival, CSS, and OS [24]. Similarly, analysis of a Japanese cohort of 124 patients with UTUC undergoing radical nephroureterectomy identified AGR < 1.40 as an independent prognostic factor for recurrence-free survival, CSS, and OS [25]. Finally, another Japanese study comprising 105 patients with UTUC undergoing radical nephroureterectomy reported that AGR < 1.24 was an independent predictor for both worse disease-free and overall survivals [26]. Our results are consistent with those of these previous reports and add further evidence in this field.
The association between a low AGR and poor outcome of patients with cancer requires further research. However, the available data show that poor nutritional status or hypoalbuminemia is a negative prognostic factor for certain malignancies [13, 15, 16]. Chronic inflammation involving serum globulins plays a crucial role in tumor proliferation, immune evasion, and metastasis. These serum globulins secreted by tumor-related cells reportedly promote tumor development, immunosuppression, and metastasis [16]. A low AGR may thus reflect the degree of poor nutritional status (hypoalbuminemia) and tumor progression (hyperglobulinemia) in a more sensitive manner than either measure alone and may therefore serve as a highly significant prognostic biomarker. Based on a similar concept as AGR (i.e. use of a ratio), several systemic inflammatory markers, such as the neutrophil-to-lymphocyte ratio [11, 12, 28], platelet-to-lymphocyte ratio [28], and lymphocyte-to-monocyte ratio [28], have been established and well-investigated in the field of oncology, including urothelial carcinoma.
The major limitations of this study are its retrospective, single-institutional design and the limited number of patients. Further studies with larger populations are needed to confirm our results.

Conclusions

Given the significant prognostic associations of the AGR with CSS and OS, AGRs are easy to determine in routine clinical practice, and a preoperative AGR < 1.25 might serve as a useful prognostic biomarker of patients with UTUC treated with radical nephroureterectomy.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12894-020-00700-8.

Acknowledgements

We thank Dr. Alla Bradley from Edanz Group (https://​en-author-services.​edanzgroup.​com/​) for editing a draft of this manuscript.
The present study was approved by the internal institutional review board of Kyorin University School of Medicine (approval number: 1154). This was a retrospective study, and additional informed consent was not required by the board.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRef
2.
Zurück zum Zitat Munoz J, Ellison L. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164:1523–5.CrossRef Munoz J, Ellison L. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164:1523–5.CrossRef
3.
Zurück zum Zitat Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD. Wood CG; upper tract Urothelial carcinoma collaboration. The upper tract Urothelial carcinoma collaboration. Outcomes of radical nephroureterectomy: a series from the upper tract Urothelial carcinoma collaboration. Cancer. 2009;115:1224–33.CrossRef Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD. Wood CG; upper tract Urothelial carcinoma collaboration. The upper tract Urothelial carcinoma collaboration. Outcomes of radical nephroureterectomy: a series from the upper tract Urothelial carcinoma collaboration. Cancer. 2009;115:1224–33.CrossRef
4.
Zurück zum Zitat Akaza H, Koiso K, Niijima T. Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer. 1987;59:1369–75.CrossRef Akaza H, Koiso K, Niijima T. Clinical evaluation of urothelial tumors of the renal pelvis and ureter based on a new classification system. Cancer. 1987;59:1369–75.CrossRef
5.
Zurück zum Zitat Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009;73:142–6.CrossRef Fernández MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009;73:142–6.CrossRef
6.
Zurück zum Zitat Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M. Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy. Jpn J Clin Oncol. 2016;46:554–9.CrossRef Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M. Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy. Jpn J Clin Oncol. 2016;46:554–9.CrossRef
7.
Zurück zum Zitat Shibing Y, Liangren L, Qiang W, Hong L, Turun S, Junhao L, Lu Y, Zhengyong Y, Yonghao J, Guangqing F, Yunxiang L, Dehong C. Impact of tumour size on prognosis of upper urinary tract urothelial carcinoma after radical nephroureterectomy: a multi-institutional analysis of 795 cases. BJU Int. 2016;118:902–10.CrossRef Shibing Y, Liangren L, Qiang W, Hong L, Turun S, Junhao L, Lu Y, Zhengyong Y, Yonghao J, Guangqing F, Yunxiang L, Dehong C. Impact of tumour size on prognosis of upper urinary tract urothelial carcinoma after radical nephroureterectomy: a multi-institutional analysis of 795 cases. BJU Int. 2016;118:902–10.CrossRef
8.
Zurück zum Zitat Su X, Fang D, Li X, Xiong G, Zhang L, Hao H, Gong Y, Zhang Z, Zhou L. The influence of tumor size on oncologic outcomes for patients with upper tract Urothelial carcinoma after radical Nephroureterectomy. Biomed Res Int. 2016;2016:4368943.PubMedPubMedCentral Su X, Fang D, Li X, Xiong G, Zhang L, Hao H, Gong Y, Zhang Z, Zhou L. The influence of tumor size on oncologic outcomes for patients with upper tract Urothelial carcinoma after radical Nephroureterectomy. Biomed Res Int. 2016;2016:4368943.PubMedPubMedCentral
9.
Zurück zum Zitat Waseda Y, Saito K, Ishioka J, Matsuoka Y, Numao N, Fujii Y, Sakai Y, Koga F, Okuno T, Arisawa C, Kamata S, Nagahama K, Masuda H, Yonese J, Kageyama Y, Noro A, Tsujii T, Morimoto S, Gotoh S, Kihara K. Ureteral involvement is associated with poor prognosis in upper urinary tract Urothelial carcinoma patients treated by Nephroureterectomy: a multicenter database study. Eur Urol Focus. 2016;2:296–302.CrossRef Waseda Y, Saito K, Ishioka J, Matsuoka Y, Numao N, Fujii Y, Sakai Y, Koga F, Okuno T, Arisawa C, Kamata S, Nagahama K, Masuda H, Yonese J, Kageyama Y, Noro A, Tsujii T, Morimoto S, Gotoh S, Kihara K. Ureteral involvement is associated with poor prognosis in upper urinary tract Urothelial carcinoma patients treated by Nephroureterectomy: a multicenter database study. Eur Urol Focus. 2016;2:296–302.CrossRef
10.
Zurück zum Zitat Dabi Y, El Mrini M, Duquesnes I, Delongchamps NB, Sibony M, Zerbib M, Xylinas E. Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2018;36:65–71.CrossRef Dabi Y, El Mrini M, Duquesnes I, Delongchamps NB, Sibony M, Zerbib M, Xylinas E. Impact of body mass index on the oncological outcomes of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2018;36:65–71.CrossRef
11.
Zurück zum Zitat Azuma T, Matayoshi Y, Odani K, Sato Y, Sato Y, Nagase Y, Oshi M. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer. 2013;11:337–41.CrossRef Azuma T, Matayoshi Y, Odani K, Sato Y, Sato Y, Nagase Y, Oshi M. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer. 2013;11:337–41.CrossRef
12.
Zurück zum Zitat Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, Abufaraj M, Shariat SF. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World J Urol. 2018;36:1019–29.CrossRef Vartolomei MD, Kimura S, Ferro M, Vartolomei L, Foerster B, Abufaraj M, Shariat SF. Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients. World J Urol. 2018;36:1019–29.CrossRef
13.
Zurück zum Zitat Ku JH, Kim M, Choi WS, Kwak C, Kim HH. Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol. 2014;40:753–62.CrossRef Ku JH, Kim M, Choi WS, Kwak C, Kim HH. Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol. 2014;40:753–62.CrossRef
14.
Zurück zum Zitat Yeh HC, Chien TM, Wu WJ, Li CC, Li WM, Ke HL, Chou YH, Wang CJ, Huang SP, Li CF, Liang PI, Huang CN. Is preoperative anemia a risk factor for upper tract urothelial carcinoma following radical nephroureterectomy? Urol Oncol. 2016;34:337.e1–9.CrossRef Yeh HC, Chien TM, Wu WJ, Li CC, Li WM, Ke HL, Chou YH, Wang CJ, Huang SP, Li CF, Liang PI, Huang CN. Is preoperative anemia a risk factor for upper tract urothelial carcinoma following radical nephroureterectomy? Urol Oncol. 2016;34:337.e1–9.CrossRef
15.
Zurück zum Zitat Huang J, Yuan Y, Wang Y, Chen Y, Kong W, Xue W, Chen H, Zhang J, Huang Y. Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol. 2017;35:671.e1–9.CrossRef Huang J, Yuan Y, Wang Y, Chen Y, Kong W, Xue W, Chen H, Zhang J, Huang Y. Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Urol Oncol. 2017;35:671.e1–9.CrossRef
16.
Zurück zum Zitat He J, Pan H, Liang W, Xiao D, Chen X, Guo M, He J. Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis. J Cancer. 2017;8:4002–10.CrossRef He J, Pan H, Liang W, Xiao D, Chen X, Guo M, He J. Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis. J Cancer. 2017;8:4002–10.CrossRef
17.
Zurück zum Zitat Azab BN, Bhatt VR, Vonfrolio S, Bachir R, Rubinshteyn V, Alkaied H, Habeshy A, Patel J, Picon AI, Bloom SW. Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg. 2013;206:764–70.CrossRef Azab BN, Bhatt VR, Vonfrolio S, Bachir R, Rubinshteyn V, Alkaied H, Habeshy A, Patel J, Picon AI, Bloom SW. Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients. Am J Surg. 2013;206:764–70.CrossRef
18.
Zurück zum Zitat Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer. 2015;15:347.CrossRef Shibutani M, Maeda K, Nagahara H, Ohtani H, Iseki Y, Ikeya T, Sugano K, Hirakawa K. The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. BMC Cancer. 2015;15:347.CrossRef
19.
Zurück zum Zitat Yoshino Y, Taguchi A, Shimizuguchi T, Nakajima Y, Takao M, Kashiyama T, Furusawa A, Kino N, Yasugi T. A low albumin to globulin ratio with a high serum globulin level is a prognostic marker for poor survival in cervical cancer patients treated with radiation based therapy. Int J Gynecol Cancer. 2019;29:17–22.CrossRef Yoshino Y, Taguchi A, Shimizuguchi T, Nakajima Y, Takao M, Kashiyama T, Furusawa A, Kino N, Yasugi T. A low albumin to globulin ratio with a high serum globulin level is a prognostic marker for poor survival in cervical cancer patients treated with radiation based therapy. Int J Gynecol Cancer. 2019;29:17–22.CrossRef
20.
Zurück zum Zitat Liu J, Dai Y, Zhou F, Long Z, Li Y, Liu B, Xie D, Tang J, Tan J, Yao K, Zhang Y, Tang Y, He L. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol. 2016;34:484.e1–8.CrossRef Liu J, Dai Y, Zhou F, Long Z, Li Y, Liu B, Xie D, Tang J, Tan J, Yao K, Zhang Y, Tang Y, He L. The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy. Urol Oncol. 2016;34:484.e1–8.CrossRef
21.
Zurück zum Zitat Niwa N, Matsumoto K, Ide H, Nagata H, Oya M. Prognostic value of pretreatment albumin-to-globulin ratio in patients with non-muscle-invasive bladder Cancer. Clin Genitourin Cancer. 2018;16:e655–61.CrossRef Niwa N, Matsumoto K, Ide H, Nagata H, Oya M. Prognostic value of pretreatment albumin-to-globulin ratio in patients with non-muscle-invasive bladder Cancer. Clin Genitourin Cancer. 2018;16:e655–61.CrossRef
22.
Zurück zum Zitat Koparal MY, Polat F, Çetin S, Bulut EC, Sözen TS. Prognostic role of preoperative albumin to globulin ratio in predicting survival of clear cell renal cell carcinoma. Int Braz J Urol. 2018;44:933–46.CrossRef Koparal MY, Polat F, Çetin S, Bulut EC, Sözen TS. Prognostic role of preoperative albumin to globulin ratio in predicting survival of clear cell renal cell carcinoma. Int Braz J Urol. 2018;44:933–46.CrossRef
23.
Zurück zum Zitat Zhang B, Yu W, Zhou LQ, He ZS, Shen C, He Q, Li J, Liu LB, Wang C, Chen XY, Fan Y, Hu S, Zhang L, Han WK, Jin J. Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract Urothelial carcinoma. PLoS One. 2015;10:e0144961.CrossRef Zhang B, Yu W, Zhou LQ, He ZS, Shen C, He Q, Li J, Liu LB, Wang C, Chen XY, Fan Y, Hu S, Zhang L, Han WK, Jin J. Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract Urothelial carcinoma. PLoS One. 2015;10:e0144961.CrossRef
24.
Zurück zum Zitat Xu H, Tan P, Ai J, Huang Y, Lin T, Yang L, Wei Q. Prognostic impact of preoperative albumin-globulin ratio on oncologic outcomes in upper tract Urothelial carcinoma treated with radical Nephroureterectomy. Clin Genitourin Cancer. 2018;16:e1059–68.CrossRef Xu H, Tan P, Ai J, Huang Y, Lin T, Yang L, Wei Q. Prognostic impact of preoperative albumin-globulin ratio on oncologic outcomes in upper tract Urothelial carcinoma treated with radical Nephroureterectomy. Clin Genitourin Cancer. 2018;16:e1059–68.CrossRef
25.
Zurück zum Zitat Otsuka M, Kamasako T, Uemura T, Takeshita N, Shinozaki T, Kobayashi M, Komaru A, Fukasawa S. Prognostic role of the preoperative serum albumin : globulin ratio after radical nephroureterectomy for upper tract urothelial carcinoma. Int J Urol. 2018;25:871–8.CrossRef Otsuka M, Kamasako T, Uemura T, Takeshita N, Shinozaki T, Kobayashi M, Komaru A, Fukasawa S. Prognostic role of the preoperative serum albumin : globulin ratio after radical nephroureterectomy for upper tract urothelial carcinoma. Int J Urol. 2018;25:871–8.CrossRef
26.
Zurück zum Zitat Fukushima H, Kobayashi M, Kawano K, Morimoto S. Prognostic value of albumin/globulin ratio in patients with upper tract Urothelial carcinoma patients treated with radical Nephroureterectomy. Anticancer Res. 2018;38:2329–34.PubMed Fukushima H, Kobayashi M, Kawano K, Morimoto S. Prognostic value of albumin/globulin ratio in patients with upper tract Urothelial carcinoma patients treated with radical Nephroureterectomy. Anticancer Res. 2018;38:2329–34.PubMed
27.
Zurück zum Zitat McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41:1690–6.CrossRef McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41:1690–6.CrossRef
28.
Zurück zum Zitat Cantiello F, Russo GI, Vartolomei MD, ARA F, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, Ferro M. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2018;1:403–10.CrossRef Cantiello F, Russo GI, Vartolomei MD, ARA F, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R, Serretta V, Busetto GM, Scafuro C, Perdonà S, Borghesi M, Schiavina R, Cioffi A, De Berardinis E, Almeida GL, Bove P, Lima E, Ucciero G, Matei DV, Crisan N, Verze P, Battaglia M, Guazzoni G, Autorino R, Morgia G, Damiano R, de Cobelli O, Mirone V, Shariat SF, Ferro M. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2018;1:403–10.CrossRef
Metadaten
Titel
Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma
verfasst von
Shota Omura
Satoru Taguchi
Shogo Miyagawa
Ryuki Matsumoto
Mio Samejima
Naoki Ninomiya
Kazuki Masuda
Yu Nakamura
Tsuyoshi Yamaguchi
Manami Kinjo
Mitsuhiro Tambo
Takatsugu Okegawa
Eiji Higashihara
Hiroshi Fukuhara
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Urology / Ausgabe 1/2020
Elektronische ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00700-8

Weitere Artikel der Ausgabe 1/2020

BMC Urology 1/2020 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.